NO20025154D0 - Imidazopyrimidinderivater og triazolpyrimidinderivater - Google Patents

Imidazopyrimidinderivater og triazolpyrimidinderivater

Info

Publication number
NO20025154D0
NO20025154D0 NO20025154A NO20025154A NO20025154D0 NO 20025154 D0 NO20025154 D0 NO 20025154D0 NO 20025154 A NO20025154 A NO 20025154A NO 20025154 A NO20025154 A NO 20025154A NO 20025154 D0 NO20025154 D0 NO 20025154D0
Authority
NO
Norway
Prior art keywords
sup
sub
derivatives
optionally substituted
imidazopyrimidine
Prior art date
Application number
NO20025154A
Other languages
English (en)
Other versions
NO20025154L (no
Inventor
Takeshi Yura
Arnel B Concepcion
Gyoonhee Han
Makiko Marumo
Hiroko Katsumata
Norihiro Kawamura
Toshio Kokubo
Hiroshi Komura
Yingfu Li
Timothy Bruno Lowinger
Muneto Mogi
Noriyuki Yamamoto
Nagahiro Yoshida
Scott C Miller
Margaret A Popp
Niko M Redmann
Martha E Rodriguez
William J Scott
Ming Wang
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO20025154D0 publication Critical patent/NO20025154D0/no
Publication of NO20025154L publication Critical patent/NO20025154L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20025154A 2000-04-28 2002-10-25 Imidazopyrimidinderivater og triazolpyrimidinderivater NO20025154L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000128870A JP2001302667A (ja) 2000-04-28 2000-04-28 イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
PCT/EP2001/004357 WO2001083485A1 (en) 2000-04-28 2001-04-17 Imidazopyrimidine derivatives and triazolopyrimidine derivatives

Publications (2)

Publication Number Publication Date
NO20025154D0 true NO20025154D0 (no) 2002-10-25
NO20025154L NO20025154L (no) 2002-10-25

Family

ID=18638240

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025154A NO20025154L (no) 2000-04-28 2002-10-25 Imidazopyrimidinderivater og triazolpyrimidinderivater

Country Status (38)

Country Link
US (1) US6911443B2 (no)
EP (1) EP1278750B1 (no)
JP (2) JP2001302667A (no)
KR (1) KR20030009456A (no)
CN (1) CN1263756C (no)
AR (1) AR033367A1 (no)
AT (1) ATE272639T1 (no)
AU (1) AU783043B2 (no)
BG (1) BG107166A (no)
BR (1) BR0110404A (no)
CA (1) CA2407531A1 (no)
CZ (1) CZ20023551A3 (no)
DE (1) DE60104671T2 (no)
DK (1) DK1278750T3 (no)
DO (1) DOP2001000151A (no)
EE (1) EE200200606A (no)
ES (1) ES2225546T3 (no)
HK (1) HK1058362A1 (no)
HR (1) HRP20020943A2 (no)
HU (1) HUP0300846A2 (no)
IL (1) IL151919A0 (no)
MA (1) MA25746A1 (no)
MX (1) MXPA02010579A (no)
MY (1) MY141578A (no)
NO (1) NO20025154L (no)
NZ (2) NZ526221A (no)
PE (1) PE20011287A1 (no)
PL (1) PL358106A1 (no)
PT (1) PT1278750E (no)
RU (1) RU2306313C2 (no)
SI (1) SI1278750T1 (no)
SK (1) SK15332002A3 (no)
SV (1) SV2001000416A (no)
TR (1) TR200402300T4 (no)
TW (1) TWI222974B (no)
UA (1) UA72615C2 (no)
WO (1) WO2001083485A1 (no)
ZA (1) ZA200207676B (no)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60216747T2 (de) 2001-04-09 2007-10-04 Novartis Vaccines and Diagnostics, Inc., Emeryville Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten
DE60303238T2 (de) 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
WO2005037837A1 (ja) * 2003-10-17 2005-04-28 Nippon Kayaku Kabushiki Kaisha 置換２−アミノ−[１，２，４]トリアゾロ[１，５−a]ピリミジン誘導体及びその用途
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
RU2373208C2 (ru) 2004-01-31 2009-11-20 Актимис Фармасьютикалз, Инк. Производные имидазо[1,2-c]пиримидинилуксусной кислоты
WO2006004702A1 (en) * 2004-06-25 2006-01-12 Amgen Inc. Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases
JP2008510734A (ja) 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
KR20070055563A (ko) 2004-08-23 2007-05-30 와이어쓰 혈전증 및 심혈관 질병의 치료에 유용한 플라스미노겐활성화제 억제제 타입-1(ｐａｉ-1)의 조절제로서의옥사졸로-나프틸 산
EP1812439B2 (en) * 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
BRPI0607062A2 (pt) 2005-02-28 2009-08-04 Japan Tobacco Inc composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos
US7442700B2 (en) 2005-07-01 2008-10-28 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20080004295A1 (en) * 2005-10-13 2008-01-03 Gore Paul M Novel compounds
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
AU2007323725B2 (en) * 2006-11-22 2014-02-20 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
US20100298557A1 (en) 2006-12-28 2010-11-25 Taisho Pharmaceutical Co., Ltd Pyrazolopyrimidine compound
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
DK2205569T3 (da) 2007-09-25 2012-05-21 Actimis Pharmaceuticals Inc Alkylthiopyrimidiner som crth2-antagonister
AR068633A1 (es) 2007-09-25 2009-11-25 Actimis Pharmaceuticals Inc Pirimidinas sustituidas con 2-s- bencilo como antagonistas de crth2
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
SI2716157T1 (sl) 2008-12-08 2016-10-28 Gilead Connecticut, Inc., c/o Gilead Sciences, Inc. Imidazopirazinski Syk-inhibitorji
ES2744541T3 (es) 2008-12-08 2020-02-25 Gilead Connecticut Inc Inhibidores de imidazopirazina Syk
WO2010147898A2 (en) * 2009-06-15 2010-12-23 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)
MA33909B1 (fr) 2009-12-23 2013-01-02 Takeda Pharmaceutical Pyrrolidinones accoles en tant d'inhibiteurs de syk
KR101717809B1 (ko) 2010-03-11 2017-03-17 질레드 코네티컷 인코포레이티드 이미다조피리딘 ｓｙｋ 억제제
SG184870A1 (en) * 2010-04-14 2012-11-29 Array Biopharma Inc 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
JP2014513686A (ja) 2011-05-10 2014-06-05 メルク・シャープ・アンド・ドーム・コーポレーション Ｓｙｋ阻害薬としてのアミノピリミジン
EP2706852B1 (en) 2011-05-10 2018-08-22 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
EP2707357B1 (en) 2011-05-10 2017-01-18 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as syk inhibitors
WO2012167423A1 (en) 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
EP2723739B1 (en) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US9006444B2 (en) 2011-10-05 2015-04-14 Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
US8987456B2 (en) 2011-10-05 2015-03-24 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
WO2013052394A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
RU2014118954A (ru) * 2011-10-12 2015-11-20 Эррэй Биофарма Инк. 5,7-ЗАМЕЩЕННЫЕ-ИМИДАЗО[1,2-c]ПИРИМИДИНЫ
PL2799431T3 (pl) * 2011-12-28 2018-07-31 Fujifilm Corporation Nowa pochodna nikotynamidu lub jej sól
US9242984B2 (en) 2012-06-20 2016-01-26 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as Syk inhibitors
WO2013192128A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
US9376418B2 (en) 2012-06-22 2016-06-28 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (SYK) inhibitors
WO2013192088A1 (en) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9353066B2 (en) 2012-08-20 2016-05-31 Merck Sharp & Dohme Corp. Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors
WO2014048065A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
US9624210B2 (en) 2012-12-12 2017-04-18 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
US9598405B2 (en) 2012-12-21 2017-03-21 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
WO2014176216A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
WO2014176210A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
TW201601728A (zh) 2013-07-30 2016-01-16 吉李德康乃狄克公司 脾酪胺酸激酶（ＳｙＫ）抑制劑之調合物
AU2014296308C1 (en) 2013-07-30 2018-09-13 Kronos Bio, Inc. Polymorph of Syk inhibitors
MX2016007311A (es) 2013-12-04 2016-09-07 Gilead Sciences Inc Metodos para tratar canceres.
WO2015094997A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015095444A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015095445A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
WO2015138273A1 (en) 2014-03-13 2015-09-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
JP6535022B2 (ja) 2014-03-19 2019-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ヘテロアリールｓｙｋ阻害剤
BR112016028641A2 (pt) 2014-07-14 2017-08-22 Gilead Sciences Inc ?método para tratar câncer?
CA2998250A1 (en) 2015-09-11 2017-03-16 Boehringer Ingelheim International Gmbh Pyrazolyl-substituted heteroaryls and their use as medicaments
CN115028640A (zh) 2017-08-25 2022-09-09 吉利德科学公司 Syk抑制剂的多晶型物
WO2019076817A1 (en) 2017-10-19 2019-04-25 Bayer Animal Health Gmbh USE OF FUSED HETEROAROMATIC PYRROLIDONES FOR THE TREATMENT AND PREVENTION OF DISEASES IN ANIMALS
WO2019099578A1 (en) * 2017-11-14 2019-05-23 Chidren's Medical Center Corporation Use of imidazopyrimidine for modulating human immune response
US11673891B2 (en) 2017-11-14 2023-06-13 Dana-Farber Cancer Institute, Inc. Imidazopyrimidine compounds and uses thereof
WO2019235571A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 血液がんの処置剤および医薬組成物
EP3804722A4 (en) * 2018-06-06 2022-04-13 National University Corporation Hokkaido University TREATMENT AGENT AND PHARMACEUTICAL COMPOSITION AGAINST GLIOMA
WO2019235572A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 固形がんの処置剤および医薬組成物
LT3873903T (lt) 2018-10-31 2024-05-10 Gilead Sciences, Inc. Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
EP3927708A1 (en) 2019-02-22 2021-12-29 Kronos Bio, Inc. Solid forms of condensed pyrazines as syk inhibitors
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021173476A1 (en) * 2020-02-24 2021-09-02 The Trustees Of Columbia University In The City Of New York Compounds, pharmaceutical formulations, and methods for treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483987A (en) * 1983-06-20 1984-11-20 G. D. Searle & Co. 8-Substituted 7-phenyl-1,2,4-triazolo[2,3-c]pyrimidines-5-amines and amides
WO1999016755A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
EP1054004B1 (en) 1997-12-15 2008-07-16 Astellas Pharma Inc. Novel pyrimidine-5-carboxamide derivatives
US6673564B2 (en) * 1999-10-18 2004-01-06 Millennium Pharmaceuticals, Inc. Methods for using 22045, a human cyclic nucleotide phosphodiesterase

Also Published As

Publication number Publication date
MA25746A1 (fr) 2003-04-01
BG107166A (bg) 2003-06-30
CZ20023551A3 (cs) 2003-01-15
AU783043B2 (en) 2005-09-22
KR20030009456A (ko) 2003-01-29
NZ522241A (en) 2004-04-30
EE200200606A (et) 2004-04-15
JP2003535067A (ja) 2003-11-25
SV2001000416A (es) 2001-07-03
MY141578A (en) 2010-05-14
US20040054179A1 (en) 2004-03-18
DK1278750T3 (da) 2004-11-22
BR0110404A (pt) 2003-02-11
SK15332002A3 (sk) 2003-06-03
NZ526221A (en) 2005-01-28
EP1278750B1 (en) 2004-08-04
PL358106A1 (en) 2004-08-09
PE20011287A1 (es) 2002-02-27
TWI222974B (en) 2004-11-01
JP2001302667A (ja) 2001-10-31
DOP2001000151A (es) 2002-05-15
UA72615C2 (en) 2005-03-15
WO2001083485A1 (en) 2001-11-08
CN1439009A (zh) 2003-08-27
US6911443B2 (en) 2005-06-28
EP1278750A1 (en) 2003-01-29
CN1263756C (zh) 2006-07-12
MXPA02010579A (es) 2003-05-14
RU2306313C2 (ru) 2007-09-20
TR200402300T4 (tr) 2004-12-21
ZA200207676B (en) 2003-09-25
DE60104671D1 (de) 2004-09-09
AR033367A1 (es) 2003-12-17
DE60104671T2 (de) 2005-12-29
HK1058362A1 (en) 2004-05-14
ATE272639T1 (de) 2004-08-15
PT1278750E (pt) 2004-11-30
IL151919A0 (en) 2003-04-10
HRP20020943A2 (en) 2005-02-28
SI1278750T1 (en) 2005-02-28
ES2225546T3 (es) 2005-03-16
CA2407531A1 (en) 2001-10-25
HUP0300846A2 (hu) 2003-08-28
AU6220401A (en) 2001-11-12
NO20025154L (no) 2002-10-25

Similar Documents

Publication Publication Date Title
NO20025154D0 (no) Imidazopyrimidinderivater og triazolpyrimidinderivater
NO2015020I2 (no) Ceritinib eller et farmasøytisk akseptabelt salt derav
FI970317A0 (fi) Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä
EA200000334A1 (ru) Производные карбоксамидотиазолов, их получение, содержащие их фармацевтические композиции
GC0000221A (en) Pyrimidinone compounds, processes for their preparation, intermediates useful in their preparation, and pharmaceutical compositions containing them
WO1999061444A3 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
ATE301640T1 (de) Anellierte 4-carboxyamino-2-methyl-1,2,3,4- tetrahydrochinoline als cetp-hemmer
DK633088A (da) Kollagenaseinhibitorer
PE20020524A1 (es) 7-oxo-piridopirimidinas como inhibidores de quinasas
DE60001182T2 (de) Erythromycin-Derivate, ihr Verfahren zur Herstellung und ihre Verwendung als Arzneimittel
DK173783D0 (da) Fremgangsmade til fremstilling af imidazo (1,2-alfa)pyridiner
FI812183L (fi) 3,1-benzoxazin-2-oner deras framstaellning och anvaendning
EA200600046A1 (ru) Производные 6-[2-(фосфонометокси)алкокси]пиримидинов (варианты), способ их получения (варианты), фармацевтическая композиция на их основе и способ лечения вирусной инфекции
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
FI832739A (fi) 5-alkyl-1,6-naftyridin-2(1h)-oner, mellanprodukter deras framstaellning och anvaendning som hjaertlaekemedel
NO20002490D0 (no) FremgangsmÕte for fremstilling av 1,4-dihydropyridiner og forbindelser anvendt ved denne fremgangsmÕten
HUT41739A (en) Herbicidal and plant growth regulating compositions comprising novel "1-aryl-5-alkoxy-imino-alkyl-aminopyrazoles as active substance and process for preparing the novel active substances
AU2175083A (en) 2-(substituted amino)-pyrimid-4-one derivatives
HUT44012A (en) Herbicide compositions containing new aryl-tetrahydro-phtalimide derivatives and process for producing the active components
BR0010488B1 (pt) tienocicloalqu(en)ilamino-1,3,5-triazinas substituÍdas como herbicidas, processo para sua preparaÇço, mÉtodo para controle de vegetaÇço indesejÁvel, bem como uso e composiÇço herbicida.
IT1313702B1 (it) Processo per la preparazione di derivati 3-sostituiti di 4-fenil-piperidine.
DK0627429T3 (da) Loracarbefisopropanolat og fremgangsmåde til omdannelse af loracarbefisopropanolat til loracarbefmonohydrat
AU1001897A (en) Process for the stereoselective preparation of a hetero-bicyclic alcohol enantiomer
DK1250335T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af imidazopyridiner
EP1065202A4 (en) 6- (ALPHA-FLUOROALKYL) -4-PYRIMIDONES AND THEIR PRODUCTION PROCESS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application